Commonwealth of Pennsylvania Public School Empls Retrmt SYS trimmed its holdings in ResMed Inc. (NYSE:RMD) by 44.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,565 shares of the medical equipment provider’s stock after selling 9,133 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in ResMed were worth $890,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Sawtooth Solutions LLC grew its holdings in ResMed by 1.6% in the 2nd quarter. Sawtooth Solutions LLC now owns 3,167 shares of the medical equipment provider’s stock worth $247,000 after buying an additional 49 shares in the last quarter. YorkBridge Wealth Partners LLC lifted its position in ResMed by 4.9% in the second quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock worth $115,000 after purchasing an additional 69 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in ResMed by 2.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,489 shares of the medical equipment provider’s stock worth $272,000 after purchasing an additional 82 shares during the period. Toronto Dominion Bank lifted its position in ResMed by 12.8% in the second quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock worth $135,000 after purchasing an additional 197 shares during the period. Finally, Utah Retirement Systems lifted its position in ResMed by 0.8% in the second quarter. Utah Retirement Systems now owns 25,583 shares of the medical equipment provider’s stock worth $1,992,000 after purchasing an additional 200 shares during the period. 62.02% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have weighed in on RMD shares. Zacks Investment Research upgraded ResMed from a “hold” rating to a “buy” rating and set a $86.00 target price for the company in a research report on Thursday, October 12th. BMO Capital Markets upped their target price on ResMed from $70.00 to $74.00 and gave the stock a “market perform” rating in a research report on Friday, October 27th. J P Morgan Chase & Co upped their target price on ResMed from $72.00 to $73.00 and gave the stock an “overweight” rating in a research report on Monday, October 30th. Needham & Company LLC restated a “sell” rating on shares of ResMed in a research report on Friday, September 8th. Finally, Jefferies Group restated a “sell” rating and issued a $56.00 target price on shares of ResMed in a research report on Thursday, October 12th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. ResMed currently has a consensus rating of “Hold” and an average target price of $67.57.

In other news, CFO Brett Sandercock sold 1,250 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $77.05, for a total value of $96,312.50. Following the completion of the sale, the chief financial officer now owns 64,691 shares in the company, valued at $4,984,441.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Pendarvis sold 2,804 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $84.17, for a total value of $236,012.68. Following the completion of the sale, the insider now owns 97,257 shares of the company’s stock, valued at approximately $8,186,121.69. The disclosure for this sale can be found here. Insiders have sold a total of 184,693 shares of company stock valued at $15,149,955 in the last quarter. Insiders own 1.77% of the company’s stock.

Shares of ResMed Inc. (NYSE:RMD) traded up $0.83 during trading hours on Thursday, hitting $85.18. The stock had a trading volume of 444,500 shares, compared to its average volume of 853,212. ResMed Inc. has a one year low of $58.71 and a one year high of $87.81. The firm has a market cap of $11,969.59, a P/E ratio of 29.39, a PEG ratio of 1.87 and a beta of 0.78. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.72 and a quick ratio of 3.86.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, meeting analysts’ consensus estimates of $0.66. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The company had revenue of $523.66 million during the quarter, compared to the consensus estimate of $506.08 million. During the same quarter in the prior year, the firm earned $0.62 EPS. The company’s quarterly revenue was up 12.5% compared to the same quarter last year. research analysts expect that ResMed Inc. will post 3 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be given a dividend of $0.35 per share. The ex-dividend date is Wednesday, November 8th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.64%. ResMed’s dividend payout ratio (DPR) is presently 56.68%.

TRADEMARK VIOLATION WARNING: “ResMed Inc. (RMD) Position Cut by Commonwealth of Pennsylvania Public School Empls Retrmt SYS” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/12/07/resmed-inc-rmd-position-cut-by-commonwealth-of-pennsylvania-public-school-empls-retrmt-sys.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.